HaploX provides a range of services, from the initial genotypic screening of subjects to the analysis of clinical and genomic data, including genetic screening for patient enrollment, biomarker discovery, co-development of companion diagnostic, research & academic cooperation and marketing activity collaboration. R&D genetic testing solutions aim to better meet the needs of collaborative clients in drug development and scientific research.

As of now, HaploX has provided our research and development genetic testing services to over 700 biopharmaceutical companies, research institutes and other institutions. We look forward to offering 'precision' services to more biopharmaceutical companies and research institutions in the future, as well as facilitating the translation of these research findings into novel clinical applications to optimize cancer care.